GAMMA Investing’s iTeos Therapeutics ITOS Stock Holding History

GAMMA Investing’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-76	Closed	-$758	–	3889
2025 Q2	$758	Sell	76 -270	-78%	-$2.17K	﹤0.01%	3588
2025 Q1	$2.07K	Buy	346 +222	+179%	+$1.63K	﹤0.01%	3404
2024 Q4	$952	Sell	124 -147	-54%	-$1.26K	﹤0.01%	3432
2024 Q3	$2.77K	Buy	271 +62	+30%	+$946	﹤0.01%	2961
2024 Q2	$3.1K	Buy	209 +61	+41%	+$874	﹤0.01%	2739
2024 Q1	$2.02K	Buy	148 +15	+11%	+$163	﹤0.01%	2743
2023 Q4	$1.32K	Buy	+133	New	+$1.32K	﹤0.01%	2711

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing's ITOS Position: Q3 2025 in Review

GAMMA Investing sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 76 shares — an estimated $758 sold.

GAMMA Investing first reported a position in ITOS in Q4 2023 and held it in 7 quarters. The position peaked at $3.1K in Q2 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

GAMMA Investing reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
GAMMA Investing sold 76 iTeos Therapeutics shares in Q3 2025, an estimated $758.
GAMMA Investing first reported a position in iTeos Therapeutics in Q4 2023 and held it in 7 quarters.
GAMMA Investing's iTeos Therapeutics position peaked at $3.1K in Q2 2024.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on GAMMA Investing's 13F filing for Q3 2025, filed 2 Oct 2025.